Viking Therapeutics (VKTX) Change in Account Payables (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Change in Account Payables data on file, last reported at $13.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 760.24% year-over-year to $13.9 million; the trailing twelve-month figure through Mar 2026 stood at $59.5 million (up 2298.35% YoY), and the FY2025 full-year result was $43.4 million, up 1786.15% from the prior year.
• Change in Account Payables declined to $13.9 million in Q1 2026, from $48.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $48.8 million in Q4 2025 to a low of -$10.8 million in Q3 2024.
• A 5-year average of $3.9 million and a median of $1.7 million in 2022 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables slumped 10935.0% in 2024 and soared 760.24% in 2026, its largest moves.
• Tracing VKTX's Change in Account Payables over 5 years: stood at $5.4 million in 2022, then sank by 66.57% to $1.8 million in 2023, then jumped by 430.87% to $9.6 million in 2024, then surged by 410.8% to $48.8 million in 2025, then plunged by 71.48% to $13.9 million in 2026.
• Business Quant data shows VKTX's Change in Account Payables at $13.9 million in Q1 2026, $48.8 million in Q4 2025, and -$1.1 million in Q3 2025.